ArticleMolecular cancer therapeutics2020

Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor.

Remi Adelaiye-Ogala et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.